Global expansion Eurofins CDMO is actively expanding facilities in Canada (Ontario and Mississauga) and broadening HPAPI capabilities, signaling growth and increased capacity for international biopharma clients seeking scalable GMP manufacturing and development services.

HPAPI & sterile Strengthened high-potency API development and manufacturing, including sterile and non-sterile processes, creates opportunities to engage pharma companies needing safer handling, regulatory compliance, and end-to-end support for potent compounds and complex formulations.

End-to-end support With offerings spanning drug substance, formulation, analytical development, GMP manufacturing, packaging, and regulatory RA/CMC, there is a clear path to pitch integrated development programs that shorten timelines and provide single-point accountability.

Regulatory readiness Accreditations across FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada position Eurofins CDMO as a trusted partner for global regulatory strategy, enabling conversations around seamless multi-region submissions for clinical and early commercial programs.

Tech-enabled partnerships Adoption of diverse tech stack and project management capabilities supports rapid communication and streamlined collaboration, offering sales discussions around digital integration, project visibility, and accelerated development timelines for complex drug products.